Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: A systematic review

Bulletin of the World Health Organization

Volumn 91, Issue 5, 2013, Pages 377-385

  McMahon, James H ^a   Elliott, Julian H ^a   Bertagnolio, Silvia ^b   Kubiak, Rachel ^c   Jordan, Michael R ^c  

^a ALFRED HOSPITAL   (Australia)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; VIRUS RNA;

DEVELOPING WORLD; DISEASE TREATMENT; DRUG PRESCRIBING; HUMAN IMMUNODEFICIENCY VIRUS; INFECTIOUS DISEASE; PLASMA; PUBLIC HEALTH; RNA;

ANTIVIRAL THERAPY; DEVELOPING COUNTRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW; SYSTEMATIC REVIEW; VIRUS INHIBITION; VIRUS LOAD;

ANTI-RETROVIRAL AGENTS; DEVELOPING COUNTRIES; HIV INFECTIONS; HUMANS; RNA, VIRAL; WORLD HEALTH;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84877080156     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.12.112946     Document Type: Review

References (80)

1. Together we will end AIDS. Geneva: Joint United Nations Programme on HIV/AIDS; 2012.
2. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. Geneva: World Health Organization; 2010.
3. Hamers RL, Kityo C, Lange JM, de Wit TF, Mugyenyi P. Global threat from drug resistant HIV in sub-Saharan Africa. BMJ 2012;344:e4159. doi: http://dx.doi.org/10.1136/bmj.e4159 PMID:22709963
4. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008;13(Suppl 2):1-13. PMID:18578063
5. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A et al.; International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010. Recommendations of the International AIDS Society-USA panel. JAMA 2010;304:321-33. doi: http://dx.doi.org/10.1001/jama.2010.1004 PMID:20639566
6. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington: Department of Health and Human Services; 2012. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf [accessed 12 May 2012].
7. Asboe D, Aitken C, Boffito M, Booth C, Cane P, Fakoya A et al.; BHIVA Guidelines Subcommittee. British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med 2012;13:1-44. doi: http://dx.doi.org/10.1111/j.1468-1293.2011.00971.x PMID:22171742
8. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health 2010;15(Suppl 1):1-15. doi: http://dx.doi.org/10.1111/j.1365-3156.2010.02508.x PMID:20586956
9. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P et al.; Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration; ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006;367:817-824. doi: http://dx.doi.org/10.1016/S0140-6736(06)68337-2 PMID:16530575
10. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010;10:155-166. doi: http://dx.doi.org/10.1016/S1473-3099(09)70328-7 PMID:20185094
11. Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, Yerly S et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009;9:409-417. doi: http://dx.doi.org/10.1016/S1473-3099(09)70136-7 PMID:19555900
12. International AIDS Society [Internet]. Abstract search. Geneva: IAS; 2012. Available from: http://www.iasociety.org/AbstractSearch.aspx [accessed 12 February 2013].
13. 18th Conference on Retroviruses and Opportunistic Infections [Internet]. Search abstracts. Boston: CROI; 2011. Available from: http://retroconference.org/AbstractSearch/Default.aspx?Conf=20 [accessed 12 February 2013].
14. McMahon JH, Elliott JH, Bertagnolio S, Kubiak R, Jordan M. Protocol for the systematic review of virological outcomes after 12 months of antiretroviral therapy in low and middle income countries. York: University of York; 2011. Available from: http://www.crd.york.ac.uk/PROSPEROFILES/3867_STRATEGY_20130114.pdf [accessed 19 February 2013].
15. Monitoring the Declaration of Commitment on HIV/AIDS: guidelines on construction of core indicators: 2010 reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2009.
16. Next generation indicator reference guide, version 1.1: the President's Emergency Plan for AIDS Relief. Washington: US Department of Health and Human Services; 2009.
17. Monitoring and evaluation toolkit. 4th ed. Geneva: Global Fund to Fight AIDS, Tuberculosis and Malaria; 2011.
18. A guide on indicators for monitoring and reporting on the health sector response to HIV/AIDS. Geneva: World Health Organization; 2011.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials Control Clin Trials 1986;7:177-188. doi: http://dx.doi.org/10.1016/j.trstmh.2008.11.007 PMID:19110288
20. Stuart A, Ord JK. Kendall's advanced theory of statistics. 6th ed. London: Edward Arnold; 1994.
21. Ahoua L, Guenther G, Pinoges L, Anguzu P, Chaix ML, Le Tiec C et al. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infect Dis 2009;9:81. doi: http://dx.doi.org/10.1186/1471-2334-9-81 PMID:19493344
22. Keiser O, Orrell C, Egger M, Wood R, Brinkhof MW, Furrer H et al. Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared PLoS Med 2008;5:e148. doi: http://dx.doi.org/10.1186/1471-2334-9-81 PMID:19493344
23. Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 2003;17:1369-1375. doi: http://dx.doi.org/10.1097/00002030-200306130-00011 PMID:12799558
24. Wouters E, Van Damme W, Van Loon F, van Rensburg D, Meulemans H. Public-sector ART in the Free State Province, South Africa: community support as an important determinant of outcome. Soc Sci Med 2009;69:1177-1185. doi: http://dx.doi.org/10.1016/j.socscimed.2009.07.034 PMID:19692165
25. Wouters E, Van Damme W, van Rensburg D, Meulemans H. Impact of baseline health and community support on antiretroviral treatment outcomes in HIV patients in South Africa. AIDS 2008;22:2545-2548. doi: http://dx.doi.org/10.1097/QAD.0b013e32831c5562 PMID:19005281
26. Ananworanich J, Gayet-Ageron A, Ruxrungtham K, Chetchotisakd P, Prasithsirikul W, Kiertiburanakul S et al.; Staccato Thailand Study Group. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. Antivir Ther 2008;13:375-380. PMID:18572750
27. Barth RE, van der Meer JT, Hoepelman AI, Schrooders PA, van de Vijver DA, Geelen SP et al. Effectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa. Eur J Clin Microbiol Infect Dis 2008;27:977-984. doi: http://dx.doi.org/10.1007/s10096-008-0534-2 PMID:18629557
28. Bedelu M, Ford N, Hilderbrand K, Reuter H. Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. J Infect Dis 2007;196(Suppl 3):S464-s468. doi: http://dx.doi.org/10.1086/521114 PMID:18181695
29. Bisson GP, Gross R, Bellamy S, Chittams J, Hislop M, Regensberg L et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy PLoS Med 2008;5:e109. doi: http://dx.doi.org/10.1186/1471-2334-9-81 PMID:19493344
30. Blacher RJ, Muiruri P, Njobvu L, Mutsotso W, Potter D, Ong'ech J et al. How late is too late? Timeliness to scheduled visits as an antiretroviral therapy adherence measure in Nairobi, Kenya and Lusaka, Zambia. AIDS Care 2010;22:1323-1331. doi: http://dx.doi.org/10.1080/09540121003692235 PMID:20711886
31. Bourgeois A, Laurent C, Mougnutou R, Nkoué N, Lactuock B, Ciaffi L et al. Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon. Antivir Ther 2005;10:335-341. PMID:15865228
32. Bussmann H, Wester CW, Ndwapi N, Grundmann N, Gaolathe T, Puvimanasinghe J et al. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS 2008;22:2303-2311. doi: http://dx.doi.org/10.1097/QAD.0b013e3283129db0 PMID:18981769
33. Bussmann H, Wester CW, Thomas A, Novitsky V, Okezie R, Muzenda T et al. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial. J Acquir Immune Defic Syndr 2009;51:37-46. doi: http://dx.doi.org/10.1097/QAI.0b013e31819ff102 PMID:19282782
34. Charles M, Noel F, Leger P, Severe P, Riviere C, Beauharnais CA et al. Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals. Bull World Health Organ 2008;86:970-977. doi: http://dx.doi.org/10.2471/BLT.07.050120 PMID:19142298
35. Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, Monga B et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire. AIDS 2003;17(Suppl 3):S5-15. doi: http://dx.doi.org/10.1097/00002030-200317003-00002 PMID:14565604
36. Fatti G, Grimwood A, Bock P. Better antiretroviral therapy outcomes at primary healthcare facilities: an evaluation of three tiers of ART services in four South African provinces. PLoS One 2010;5:e12888. doi: http://dx.doi.org/10.1371/journal.pone.0012888 PMID:20877631
37. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006;367:1335-1342. doi: http://dx.doi.org/10.1016/S0140-6736(06)68580-2 PMID:16631912
38. Fielding KL, Charalambous S, Stenson AL, Pemba LF, Martin DJ, Wood R et al. Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study. BMC Infect Dis 2008;8:93. doi: http://dx.doi.org/10.1186/1471-2334-8-93 PMID:18631397
39. Gandhi NR, Moll AP, Lalloo U, Pawinski R, Zeller K, Moodley P et al.; Tugela Ferry Care and Research (TFCaRes) Collaboration. Successful integration of tuberculosis and HIV treatment in rural South Africa: the Sizonq'oba study. J Acquir Immune Defic Syndr 2009;50:37-43. doi: http://dx.doi.org/10.1097/QAI.0b013e31818ce6c4 PMID:19295333
40. Garrido C, Zahonero N, Fernándes D, Serrano D, Silva AR, Ferraria N et al. Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. J Antimicrob Chemother 2008;61:694-698. doi: http://dx.doi.org/10.1093/jac/dkm515 PMID:18218644
41. Hegazi A, Bailey RL, Ahadzie B, Alabi A, Peterson K. Literacy, education and adherence to antiretroviral therapy in The Gambia. AIDS Care 2010;22:1340-1345. doi: http://dx.doi.org/10.1080/09540121003693514 PMID:20711888
42. Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P et al.; Academic Alliance for AIDS Care and Prevention in Africa. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2007;46:187-193. doi: http://dx.doi.org/10.1097/QAI.0b013e31814278c0 PMID:17693883
43. Kouanfack C, Montavon C, Laurent C, Aghokeng A, Kenfack A, Bourgeois A et al. Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment. Clin Infect Dis 2009;48:1318-1322. doi: http://dx.doi.org/10.1086/597779 PMID:19320592
44. Landman R, Poupard M, Diallo M, Ngom Gueye NF, Diakhate N, Ndiaye B et al. Tenofovir-emtricitabine-efavirenz in HIV-I-infected adults in Senegal: a 96-week pilot trial in treatment-naive patients. J Int Assoc Physicians AIDS Care (Chic) 2009;8:379-384. doi: http://dx.doi.org/10.1177/1545109709344352 PMID:19755618
45. Laurent C, Ngom Gueye NF, Ndour CT, Gueye PM, Diouf M, Diakhaté N et al.; ANRS 1215/1290 Study Group. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr 2005;38:14-17. doi: http://dx.doi.org/10.1097/00126334-200501010-00003 PMID:15608518
46. Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung MH et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet 2010;376:1838-1845. doi: http://dx.doi.org/10.1016/S0140-6736(10)61997-6 PMID:21071074
47. Lyagoba F, Dunn DT, Pillay D, Kityo C, Robertson V, Tugume S et al.; DART Virology and Trial Team. Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring. J Acquir Immune Defic Syndr 2010;55:277-283. doi: http://dx.doi.org/10.1097/QAI.0b013e3181ea0df8 PMID:20686411
48. Moore E, Beadsworth MBJ, Chaponda M, Mhango B, Faragher B, Njala J et al. Favourable one-year ART outcomes in adult Malawians with hepatitis B and C co-infection. J Infect 2010;61:155-163. doi: http://dx.doi.org/10.1016/j.jinf.2010.04.009 PMID:20470823
49. Mujugira A, Wester CW, Kim S, Bussmann H, Gaolathe T et al. Patients with advanced HIV type 1 infection initiating antiretroviral therapy in Botswana: treatment response and mortality. AIDS Res Hum Retroviruses 2009;25:127-133. doi: http://dx.doi.org/10.1089/aid.2008.0172 PMID:19239353
50. Mutevedzi PC, Lessells RJ, Heller T, Bärnighausen T, Cooke GS, Newell M-L. Scale-up of a decentralized HIV treatment programme in rural KwaZulu-Natal, South Africa: does rapid expansion affect patient outcomes? Bull World Health Organ 2010;88:593-600. doi: http://dx.doi.org/10.2471/BLT.09.069419 PMID:20680124
51. Nachega JB, Chaisson RE, Goliath R, Efron A, Chaudhary MA, Ram M et al. Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. AIDS 2010;24:1273-1280. PMID:20453627
52. Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, Regensberg L et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr 2009;51:65-71. doi: http://dx.doi.org/10.1097/QAI.0b013e318199072e PMID:19282780
53. Ndembi N, Goodall RL, Dunn DT, McCormick A, Burke A, Lyagoba F et al.; Development of Antiretroviral Treatment in Africa Virology Group and Trial Team. Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. J Infect Dis 2010;201:106-113. doi: http://dx.doi.org/10.1086/648590 PMID:19938977
54. Oyomopito R, Lee MP, Phanuphak P, Lim PL, Ditangco R, Zhou J et al.; TREAT Asia HIV Observational Database. Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD). HIV Med 2010;11:519-529. PMID:20345881
55. Ramadhani HO, Thielman NM, Landman KZ, Ndosi EM, Gao F, Kirchherr JL et al. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis 2007;45:1492-1498. doi: http://dx.doi.org/10.1086/522991 PMID:17990233
56. Sarna A, Luchters S, Geibel S, Chersich MF, Munyao P, Kaai S et al. Short- and long-term efficacy of modified directly observed antiretroviral treatment in Mombasa, Kenya: a randomized trial. J Acquir Immune Defic Syndr 2008;48:611-619. doi: http://dx.doi.org/10.1097/QAI.0b013e3181806bf1 PMID:18645509
57. Seyler C, Anglaret X, Dakoury-Dogbo N, Messou E, Touré S, Danel C et al.; ANRS 1203 Study Group. Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire. Antivir Ther 2003;8:385-393. PMID:14640385
58. Vanni T, Morejón KM, Santana RC, Melo Ld, Ferrão SB, Amorim AP et al. Comparison of the effectiveness of initial combined antiretroviral therapy with nelfinavir or efavirenz at a university-based outpatient service in Brazil. Braz J Med Biol Res 2007;40:963-969. doi: http://dx.doi.org/10.1590/S0100-879X2007000700011 PMID:17653450
59. Bertagnolio S, Kelley K, Saadani Hassani A, Obeng-Aduasare Y, Jordan M. Surveillance of transmitted and acquired HIV drug resistance using WHO surveys in resource-limited settings. In: Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections, 27 February to 2 March 2011, Boston, United States of America. Alexandria: CROI; 2011. Available from: http://www.retroconference.org/2011/Abstracts/41940.htm [accessed 24 January 2013].
60. Calmy A, Balestre E, Boulle A, Thiébaut R, Bonnet F, Sprinz E et al. Prediction of CD4 cell count slope in patients with virological failure to first-line of antiretroviral combinations in resource-limited settings. Geneva: International AIDS Society 2010 (abstract CDB081 2009 11/23/2010). Available from: http://www.iasociety.org/Default.aspx?pageId=11&abstractId=200722018 [accessed 24 January 2013].
61. Chang L, Kagaayi J, Nakigozi G, Ssempijja V, Serwadda D, Packer A et al. Effect of peer health workers and a mobile phone support intervention on AIDS care in Rakai, Uganda: a cluster-randomized trial. Geneva: International AIDS Society; 2010 (abstract WEPED158 2009 11/23/2010). Available from: http://www.iasociety.org/Default.aspx?pageId=11&abstractId=200722818 [accessed 24 January 2013].
62. Chasombat S, Kantipong P, Pathipvanich P, Luakamlung N, Malai S, Kohreanudom S et al. Thailand national surveillance system to determine the development of HIV drug resistance among ARV treated patients. Geneva: International AIDS Society; 2010. (abstract THPE0427 2010 11/23/2010). Available from: http://www.iasociety.org/Default.aspx?pageId=11&abstractId=200739558 [accessed 24 January 2013].
63. Crabtree-Ramírez B, Caro-Vega Y, Sierra-Madero J. Late diagnosis of HIV infection results in a higher mortality but not in virological failure after starting HAART. Geneva: International AIDS Society; 2010 (abstract THPE0122 2010 11/23/2010). Available from: http://www.iasociety.org/Default.aspx?pageId=11&abstractId=200740133 [accessed 24 January 2013].
64. Lockman S, Smeaton L, Ogwu A, Shapiro R, Leidner J, Powis K et al. Long-term maternal and pediatric virologic outcomes on nevirapine-based HAART following receipt of peripartum single-dose nevirapine or placebo, Botswana. In: Proceedings of the 16th Conference on Retroviruses and Opportunistic Infections, 8-11 February 2009, Montréal, Canada. Alexandria: CROI; 2009. Available from: http://www.retroconference.org/2009/Abstracts/36058.htm [accessed 24 January 2013].
65. Messou E, Chaix M-L, Gabillard D, Minga A, Losina E, N'Dri-Yoman T et al. Strong association between medication possession ratio and early virological outcomes in adults on ART in Côte d'Ivoire. In: Proceedings of the 17th Conference on Retroviruses and Opportunistic Infections, 16-19 February 2010, San Francisco, United States of America. Alexandria: CROI; 2010. Available from: http://www.retroconference.org/2010/Abstracts/38493.htm [accessed 24 January 2013].
66. Ratsela A, Polis M. Phidisa II: A randomized 2x2 factorial trial comparing initial therapy of efavirenz with lopinavir/ritonavir and zidovudine + didanosine with stavudine + lamivudine in treatment-naïve HIV-infected persons with < 200 CD4+ cells/mm3 or a prior AIDS diagnosis. In: Proceedings of the 16th Conference on Retroviruses and Opportunistic Infections, 8-11 February 2009, Montréal, Canada. Alexandria: CROI; 2009. Available from: http://www.retroconference.org/2009/Abstracts/34300.htm [accessed 24 January 2013].
67. Reynolds S, Sendagire H, Newell K, Castelnuovo B, Kiragga A, Namugga I et al. Routine VLM reduces the rate of accumulated genotypic resistance to commonly used ART in Uganda. In: Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections, 27 February to 2 March 2011, Boston, United States of America. Alexandria: CROI; 2011. Available from: http://www.retroconference.org/2011/Abstracts/41522.htm [accessed 24 January 2013].
68. Scarsi K, Darin K, Rawizza H, Meloni S, Chang C, Olaitan R et al. TDF-3TC-NVP is inferior to AZT-3TC-NVP in a large ART program in Nigeria. Geneva: International AIDS Society; 2010 (abstract THPE0115 2010 11/23/2010). Available from: http://www.iasociety.org/Default.aspx?pageId=11&abstractId=200738740 [accessed 24 January 2013].
69. Stafford K, Hossain M, Mesubi R, Etienne M, Oshi R, Bositis A et al. Viral suppression outcomes of patients using nevirapine in combination with tenofovir and a cytosine analog (3TC or FTC) as a first line regimen in resource limited settings. Geneva: International AIDS Society; 2010 (abstract CDB080 2009 11/23/2010). Available from: http://www.iasociety.org/Default.aspx?pageId=11&abstractId=200721588 [accessed 24 January 2013].
70. van Leeuwen R, Katlama C, Murphy RL, Squires K, Gatell J, Horban A et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003;17:987-999. doi: http://dx.doi.org/10.1097/00002030-200305020-00007 PMID:12700448
71. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999;341:1865-1873. doi: http://dx.doi.org/10.1056/NEJM199912163412501 PMID:10601505
72. Bartlett JA, Fath MJ, Demasi R, Hermes A, Quinn J, Mondou E et al. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 2006;20:2051-2064. doi: http://dx.doi.org/10.1097/01.aids.0000247578.08449.ff PMID:17053351
73. Bansi L, Sabin C, Gilson R, Gazzard B, Leen C, Anderson J et al.; UK Collaborative HIV Cohort Study. Virological response to initial antiretroviral regimens containing abacavir or tenofovir. J Infect Dis 2009;200:710-714. doi: http://dx.doi.org/10.1086/605024 PMID:19635022
74. Uy J, Armon C, Buchacz K, Wood K, Brooks JT; HOPS Investigators. Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure. J Acquir Immune Defic Syndr 2009;51:450-453. doi: http://dx.doi.org/10.1097/QAI.0b013e3181acb630 PMID:19474757
75. Moore DM, Mermin J, Awor A, Yip B, Hogg RS, Montaner JS. Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr 2006;43:436-439. doi: http://dx.doi.org/10.1097/01.qai.0000243105.80393.42 PMID:17019367
76. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach -2006 revision. Geneva: World Health Organization; 2006.
77. Hoffmann CJ, Charalambous S, Sim J, Ledwaba J, Schwikkard G, Chaisson RE et al. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis 2009;49:1928-3195. doi: http://dx.doi.org/10.1086/648444 PMID:19911963
78. Wilson D, Keiluhu AK, Kogrum S, Reid T, Seriratana N, Ford N et al. HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand. Trans R Soc Trop Med Hyg 2009;103:601-606. doi: http://dx.doi.org/10.1016/j.trstmh.2008.11.007 PMID:19110288
79. Glaser R. Instructional technology and the measurement of learning outcomes: some questions. In: Notterman JM, editor. The evolution of psychology: fifty years of the American Psychologist. Washington: American Psychological Association; 1963. pp. 337-342.
80. HIV drug resistance early warning indicators: World Health Organization indicators to monitor HIV drug resistance prevention at antiretroviral treatment sites. June 2010 update. Geneva: World Health Organization; 2010. Available from: www.unaids.org.br/biblioteca/links/OPAS.../OPAS%2014.pdf [accessed 21 February 2013].